Literature DB >> 8627833

Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system.

S Arver1, A S Dobs, A W Meikle, R P Allen, S W Sanders, N A Mazer.   

Abstract

PURPOSE: The effects of androgen replacement via a nonscrotal permeation enhanced testosterone transdermal system on the sexual function of men with hypogonadism were assessed.
MATERIALS AND METHODS: An open label, multicenter study of testosterone supplementation and withdrawal was conducted with sexual function assessed by the Watts and Davidson questionnaires and RigiScan monitoring.
RESULTS: When comparing results obtained during use of the testosterone transdermal system (with normalized testosterone levels) and during the androgen withdrawal period, nocturnal erections occurred more frequently with longer duration and greater rigidity, and patient assessments of sexual desire and weekly number of erections were higher.
CONCLUSIONS: Sexual function improved significantly in men with hypogonadism treated with the testosterone transdermal system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627833

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.

Authors:  Marie-Laure Leichtnam; Hervé Rolland; Patrick Wüthrich; Richard H Guy
Journal:  Pharm Res       Date:  2006-06-09       Impact factor: 4.200

2.  Relationship between testosterone and erectile dysfunction.

Authors:  J Rajfer
Journal:  Rev Urol       Date:  2000

Review 3.  Treating erectile dysfunction when PDE5 inhibitors fail.

Authors:  Chelsea N McMahon; Christopher J Smith; Ridwan Shabsigh
Journal:  BMJ       Date:  2006-03-11

Review 4.  Transdermal testosterone.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 5.  Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members.

Authors:  H L Tan
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 6.  [Pharmacotherapy of pituitary diseases].

Authors:  B Gutt; B Steffin; J Schopohl
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

Review 7.  Risks versus benefits of testosterone therapy in elderly men.

Authors:  S Basaria; A S Dobs
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 8.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Transdermal testosterone delivery: testosterone patch and gel.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  World J Urol       Date:  2003-10-09       Impact factor: 4.226

Review 10.  Androgen replacement in men with hypogonadism and erectile dysfunction.

Authors:  Marion Albrecht-Betancourt; Rabih A Hijazi; Glenn R Cunningham
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.